NCT00836849已完成1 期
Randomized, 2-Way Crossover, Bioequivalence Study of Sertraline Hydrochloride 100 mg Tablets and Zoloft® 100 mg Tablets Administered as 1 x 100 mg Tablet in Healthy Subjects Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Bioequivalence based on Cmax and AUC
研究概览
简要总结
The objective of this study is to compare the rate and extent of absorption of sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference) administered as 1 x 100 mg tablet under fasting conditions.
详细描述
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be females and/or males, non-smokers, 18 years of age and older. Female subjects will be post-menopausal or surgically sterilized.
- •Post-menopausal status is defined as absence of menses for the past 12 months.
- •Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at least 6 months ago.
排除标准
- •Clinically significant illnesses within 4 weeks of the administration of study medication.
- •Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- •Any clinically significant abnormality found during medical screening.
- •Any reason which, in the opinion of the medical sub-investigator, would preven the subject from participating in the study.
- •Abnormal laboratory tests judged clinically significant.
- •Positive urine drug screen at screening
- •Positive testing for hepatitis B, hepatitis C or HIV at screening.
- •ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHG, or diastolic blood pressure lower than 50 or over 90 mmHg; or heart rate less than 50 or over 100 bpm) at screening.
- •Subjects with BMI ≥ 30.
- •History of significant alcohol abuse within six months of the screening visit or any indication of the regular use of more than two units of alcohol per day (1 Unit = 150 mL of wine or 360 mL of beer or 45 mL of alcohol 40%)
- •History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana) within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine (PCP) and crack) within 1 year of the screening visit.
- •Any food allergy, intolerance, restriction or special diet that, in the opinion of the medical sub-investigator, contraindicates the subject's participation in this study.
- •History of allergic reactions to sertraline or other related drugs (e.g. fluoxetine hydrochloride, fluvoxamine hydrochloride, paroxetine hydrochloride).
- •Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin; examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin, ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine), use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
- •Use of prescription medication within 14 days prior to administration of study medication or over-the-counter products (including natural products, vitamins, garlic as supplement and products containing dextromethorphan) within 7 days prior to administration of study medication, except for topical products without systemic absorption.
- •Subjects who have had a depot injection or an implant of any drug 3 months prior to administration of study medication.
- •Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to administration of the study medication as follows: less than 300 mL of whole blood within 30 days or; 300 mL to 500 mL of whole blood within 45 days or; more than 500 mL of whole blood within 56 days.
- •Positive alcohol breath test at screening.
- •Subjects who have consumed food or beverages containing grapefruit (3.g. fresh, canned, or frozen) within 7 days prior to administration of the study medication.
- •Past history of bipolar affective disorder or other active psychiatric diagnosis.
- •History of seizures.
- •Subjects with a clinically significant history of renal, hepatic or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study.
- •Subjects who have used tobacco in any form within the 90 days preceding study drug administration.
- •Intolerance to venipuncture.
- •Breast-feeding subjects.
- •Positive urine pregnancy test at screening (performed on all females).
研究组 & 干预措施
1
Experimental
干预措施: Sertraline hydrochloride 100 mg Tablets (Drug)
2
Active Comparator
干预措施: Zoloft® 100 mg Tablets (Drug)
结局指标
主要结局
Bioequivalence based on Cmax and AUC
时间窗: 3 weeks
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Sertraline Hydrochloride 100 mg Tablets, FedHealthyNCT00836667Teva Pharmaceuticals USA18
已完成
1 期
Paroxetine Hydrochloride 40 mg Tablets Under Fasting ConditionsHealthyNCT00841698Teva Pharmaceuticals USA50
已完成
1 期
Paroxetine Hydrochloride 40 mg Tablets Under Fed ConditionsHealthyNCT00841659Teva Pharmaceuticals USA24
已完成
1 期
Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fasting ConditionsHealthyNCT00944242Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fed ConditionsHealthyNCT00946036Torrent Pharmaceuticals Limited